APA (7th ed.) Citation

Yang, M., Zhang, J., Wei, D., Yu, T., Chen, Z., Liu, X., & Zhu, H. (2024, February). Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy. BMC Cancer.

Chicago Style (17th ed.) Citation

Yang, Meng, Jingwen Zhang, Dongqun Wei, Tianyi Yu, Zeyu Chen, Xin Liu, and Haitao Zhu. "Inflammatory Markers Predict Survival in Patients with Postoperative Urothelial Carcinoma Receiving Tislelizumab (PD-1 Inhibitor) Adjuvant Therapy." BMC Cancer Feb. 2024.

MLA (9th ed.) Citation

Yang, Meng, et al. "Inflammatory Markers Predict Survival in Patients with Postoperative Urothelial Carcinoma Receiving Tislelizumab (PD-1 Inhibitor) Adjuvant Therapy." BMC Cancer, Feb. 2024.